Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Inclusion Criteria:

Diagnosis of multiple myeloma (MM)

Salmon-Durie stage IIA or IIIA OR progressive stage IA disease

Meets at least 1 major AND 1 minor criterion OR at least 3 minor criteria

The following are considered major criteria:

Plasmacytoma on tissue biopsy
Bone marrow plasmacytosis with >= 30% plasma cells
Monoclonal globulin spike on serum protein electrophoresis exceeding 3.5 g/dL for immunoglobulin (Ig) G peaks or 2.0 g/dL for IgA peaks OR the presence of Bence-Jones protein of >= 1 g/24 hour-urine collection

The following are considered minor criteria:

Bone marrow plasmacytosis 10-29%
Monoclonal globulin spike present, but less than the levels defined for a major criterion
Lytic bone lesion
Decrease in normal IgM < 50 mg/dL, IgA < 100 mg/dL, or IgG < 600 mg/dL
No non-secretory MM (absent serum or urinary M-protein)
Failed at least 1 prior systemic therapy* (e.g., chemotherapy, high-dose corticosteroids, thalidomide, or bortezomib) for the treatment of MM
No solitary plasmacytoma
Performance status - ECOG 0-2
More than 6 months
Absolute neutrophil count > 1,200/mm^3
Platelet count > 75,000/mm^3
AST and ALT =< 2.5 times upper limit of normal (ULN)
Bilirubin =< 1.5 times ULN
Creatinine =< 1.5 times ULN
No symptomatic congestive heart failure
No unstable angina pectoris
No cardiac arrhythmia
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
Fasting cholesterol =< 350 mg/dL
Triglycerides =< 400 mg/dL
No other concurrent uncontrolled illness
No active or ongoing infection requiring oral or IV antibiotics
No prior allergic reaction to compounds of similar chemical or biological composition to CCI-779

No other prior or concurrent malignancy or myelodysplasia except for the following:

Basal cell or squamous cell skin cancer
Carcinoma in situ of the cervix
Localized cancer treated with surgery only with no evidence of disease for > 5 years
No psychiatric illness or social situation that would preclude study compliance
More than 4 weeks since prior thalidomide and recovered
Prior high-dose chemotherapy and stem cell transplantation allowed
More than 4 weeks since prior chemotherapy and recovered
More than 4 weeks since prior high-dose corticosteroids and recovered
More than 4 weeks since prior bortezomib and recovered
More than 4 weeks since other prior anti-myeloma systemic therapy and recovered
No concurrent combination antiretroviral therapy for HIV-positive patients
No other concurrent investigational agents
No other concurrent anticancer therapy